T-E Meds and Orient EuroPharma Forge Licensing Agreement for TE-1146
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to
Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been
Join Dr. Art Hsing-Mao Chu, CEO of T-E Meds, at World ADC San Diego 2024 on Nov 4th to hear
The annual Taiwan Healthcare+ Expo will be held from December 5 to 8, 2024, at Hall 1 of the Nangang
Dr. Kun-Po Li, the director of business development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum –
Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian
We are proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, was invited to present at the
Dr. Tse Wen Chang, Chairman and CEO of Immunwork, and Dr. Art Hsing-Mao Chu, CEO of T-E Meds, have been
The 2024 Tang Prize in Biopharmaceutical Science has cast a spotlight on GLP-1 receptor agonists, sparking a global race among
Exciting news! Our latest published paper offers promising solutions for multiple myeloma treatment through ADC technology platform! We are thrilled